Neurocrine Biosciences, Inc. (NBIX), Thursday announced data from the KINECT-HD study regarding the positive impact of Ingrezza capsules on emotional health and psychiatric stability in patients with chorea associated with Huntington's disease.
The company explained that people with Huntington's disease, a hereditary progressive neurodegenerative disorder, often suffer from chorea, an abnormal involuntary movement disorder.
During the phase 3 study, the effects of Ingrezza were compared to that of placebo using the Unified Huntington's Disease Rating Scale - Total Maximal Chorea score.
The findings revealed that the consistent efficacy of Ingrezza in reducing chorea across various subgroups and its potential positive impact on emotional health in patients.
Currently, Neurocrine's stock is trading at $126.32, up 0.82 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.